Asked about plans for acquisitions, Pfizer said its focus is on ‘‘bolt-on’’ deals, meaning purchases of companies with complementary businesses or products, with a price tag of up to several billion dollars.
Read said Pfizer’s mid- to late-stage drug pipeline ‘‘continues to strengthen with key potential opportunities,’’ including drugs for advanced breast cancer and three other types of cancer, one for high cholesterol and a meningococcal B vaccine for adolescents and young adults.
For the full year, net income was $14.57 billion, or $1.94 per share. That was down from $10.01 billion, or $1.27 per share, in 2011. Revenue totaled $58.99 billion, down 10 percent from $65.26 billion in 2011, before generic competition slashed sales of Lipitor and schizophrenia drug Geodon.
Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma